Unlock this StockReport nowClick to Unlock

Tiziana Life Sciences Share Price

TILS 76p 0.0  0.0%
26/06/19 3.00k

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 2019E 2020E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p

FINANCIAL BRIEF: For the fiscal year ended 31 December 2018, Tiziana Life Sciences PLC revenues was not reported. Net loss decreased 11% to £6M. Lower net loss reflects Research and development costs decrease of 12% to £4.1M (expense), Operating Expenses decrease of 7% to £3.3M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -£0.06 to -£0.05. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Dec '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: 5.00
(+557.91% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (£) (£) (p) (£)
Consensus Estimate
1m Change
3m Change
1 broker Broker Consensus Trend
Broker Recommendations for Tiziana Life Sciences
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 1 0

Named Brokers and Analysts
H.C. Wainwright & Co., LLC , Rodman & Renshaw ,

Profile Summary

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib is in Phase II clinical trials for thymic carcinoma. The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. The Company is involved in the development of Bcl-3 inhibitors. The Company's lead clinical candidate, CB1, is a Bcl-3 inhibitor with potent anti-metastatic activity.

Directors: Gabriele Cerrone (CHM) 42, Shailubhai Kunwar (CEO) 60, Tiziano Lazzaretti (CFO) , James Tripp (COO) 47, P. Cooper (SEC) , Percy Lomax (NED) , Willy Simon (NED) 64, Leopoldo Zambeletti (NED) ,

No. of Employees: 10 No. of Shareholders: n/a

Last Annual December 31st, 2018
Last Interim December 31st, 2018
Incorporated February 11, 1998
Public Since May 9, 2000
Shares in Issue 136,463,818
Free Float 38.8m (28.4%)
Sector Financials
Industry Collective Investments
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

TILS Share Price Performance TILS Share Price Quote
0.0  0.0%
Traded 3:04pm · Minimum 15 min delayed · NMS: 3.00k

Latest TILS News Announcements (delayed)

Upcoming TILS Events

Recent ↓
Thursday 4th April, 2019
Full Year 2018 Tiziana Life Sciences PLC Earnings Release
Monday 24th September, 2018
Half Year 2018 Tiziana Life Sciences PLC Earnings Release
Thursday 24th May, 2018 (estimate)
Full Year 2017 Tiziana Life Sciences PLC Earnings Release
Friday 29th September, 2017
Half Year 2017 Tiziana Life Sciences PLC Earnings Release
Tuesday 23rd May, 2017
Full Year 2016 Tiziana Life Sciences PLC Earnings Release
Thursday 29th September, 2016
Half Year 2016 Tiziana Life Sciences PLC Earnings Release
Tuesday 7th June, 2016
Full Year 2015 Tiziana Life Sciences PLC Earnings Release
Thursday 25th June, 2015 (estimate)
Tiziana Life Sciences PLC Annual Shareholders Meeting
Wednesday 25th June, 2014
Tiziana Life Sciences PLC Annual Shareholders Meeting

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.

Should you buy TILS

Access TILS Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis